Gilead Sciences (NASDAQ:GILD) Price Target Raised to $80.00 at Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD) had its price target lifted by research analysts at Cantor Fitzgerald from $70.00 to $80.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential downside of 17.23% from the company’s current price.

Several other equities analysts have also issued reports on the stock. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $74.00 to $96.00 in a report on Monday, October 21st. BMO Capital Markets boosted their price objective on Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Barclays lifted their target price on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Finally, Truist Financial increased their price target on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Ten equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $88.65.

Gilead Sciences Trading Up 5.4 %

GILD traded up $4.96 during midday trading on Thursday, hitting $96.65. 2,920,497 shares of the company were exchanged, compared to its average volume of 6,993,893. The firm has a market capitalization of $120.33 billion, a P/E ratio of 117.88, a P/E/G ratio of 3.13 and a beta of 0.17. The firm’s 50 day moving average price is $84.58 and its 200-day moving average price is $74.67. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $98.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.29 earnings per share. As a group, equities analysts forecast that Gilead Sciences will post 3.75 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.29% of the stock is owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at approximately $462,000. Envestnet Portfolio Solutions Inc. lifted its position in shares of Gilead Sciences by 31.8% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 112,743 shares of the biopharmaceutical company’s stock worth $8,258,000 after acquiring an additional 27,211 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Gilead Sciences in the first quarter worth $573,000. AIA Group Ltd purchased a new position in shares of Gilead Sciences in the first quarter valued at $1,684,000. Finally, SG Americas Securities LLC raised its stake in shares of Gilead Sciences by 51.2% during the 1st quarter. SG Americas Securities LLC now owns 154,992 shares of the biopharmaceutical company’s stock valued at $11,353,000 after purchasing an additional 52,494 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.